Yahoo Finance

H.C. Wainwright downgraded Eyenovia (EYEN) to Neutral from Buy with a price target of $2, down from $12. Based on the announced independent data review committee determining the Phase 3 CHAPERONE study did not meet its primary endpoint of less than 0.5 diopter progression in visual acuity over the three-year timeframe, the Optejet device continues to need a substantial indication for mainstream adoption, the analyst tells investors in a research note. The firm says that with the CHAPERONE study discontinued for full dataset review and next program steps forthcoming, it was noted by management that a business combination, reverse merger, asset sales or a combination of those approaches could be possible as strategic options.

Don't Miss our Black Friday Offers:

• Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks

• Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on EYEN:

• Eyenovia downgraded to Market Perform from Outperform at William Blair

• Eyenovia downgraded to Hold from Buy at Brookline

• Eyenovia plans to terminate Phase 3 CHAPERONE study after DRC review

• Eyenovia price target lowered to $4.50 from $7 at Ladenburg

• Eyenovia’s Strategic Advances and Q3 Financials